Wan Li, Dong Ding-Hui, Wu Xiao-Ning, Ding Hong-Fan, Lu Qiang, Tian Yong, Zhang Xu-Feng, Li Wenzhi
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China (mainland).
Luonan County Hospital, Shangluo, Shaanxi, China (mainland).
Med Sci Monit. 2020 Oct 16;26:e926797. doi: 10.12659/MSM.926797.
BACKGROUND The aim of the present study was to evaluate the prognosis among patients with a single large hepatocellular carcinoma (HCC) >5 cm compared with other patients in Barcelona Clinic Liver Cancer (BCLC) stage A or stage B. MATERIAL AND METHODS Data on patients with BCLC stage A/B HCC were collected between 2008 and 2012. BCLC stage A was subclassified as A1 (single tumor, 2-5 cm, or 2-3 nodules £3 cm), or A2 (single tumor >5 cm). Overall survival (OS) was evaluated and compared. RESULTS Among 1005 patients with HCC, 455 were stage A1, 188 were stage A2, and 362 were stage B. The OS of stage A2 patients was significantly worse than that of stage A1 patients (median survival, 30.6 vs. 43.2 months, p5 cm had a comparable survival with BCLC stage B. HCC >5 cm should therefore be classified as an intermediate stage.
背景 本研究的目的是评估单个直径>5 cm的大肝细胞癌（HCC）患者与巴塞罗那临床肝癌（BCLC）分期A或B期的其他患者的预后情况。材料与方法 收集2008年至2012年期间BCLC分期A/B期HCC患者的数据。BCLC分期A进一步细分为A1期（单个肿瘤，直径2 - 5 cm，或2 - 3个直径≤3 cm的结节）或A2期（单个肿瘤>5 cm）。评估并比较总生存期（OS）。结果 在1005例HCC患者中，455例为A1期，188例为A2期，362例为B期。A2期患者的OS明显差于A1期患者（中位生存期分别为30.6个月和43.2个月，p<0.001）。A2期患者的生存情况与BCLC分期B期患者相当。因此，直径>5 cm的HCC应归类为中期。
